Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01908010 | Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors | PHASE1 | COMPLETED | 20 | — | — | Jul 1, 2013 | Nov 1, 2013 | Dec 11, 2013 | 3 | United States |
Hematology, Chemistry, Urinalysis
| Arm | Type | Description |
|---|---|---|
| Group 1, low dose | EXPERIMENTAL | ABT-354 |
| Group 2, high dose | EXPERIMENTAL | ABT-354 |
| Name | Type | Description |
|---|---|---|
| ABT-354 | DRUG | ABT-354 Low Dose |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Meets the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria for probable Alzheimer's Disease * Has a Mini-Mental State Examination total score of 16 to 26, inclusive, at Screening * Has a Mo...